Paradigm shifts in haemophilia A therapy with emicizumab prophylaxis in Asia

Abstract

Over the past decade, the development of emicizumab, the first-in-class factor VIII (FVIII), a mimetic monoclonal antibody bispecific to activated factor IX and factor X, has ushered in a significant revolution in non-factor replacement therapy for patients with congenital FVIII deficiency or haemophilia A (HA).